IGF—ⅠR抑制剂联合西妥昔单抗对人肝癌细胞的体外抑制作用(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 探讨西妥昔单抗与胰岛素样生长因子—Ⅰ受体(IGF—ⅠR)抑制剂aIR3对人肝癌细胞株HepG2细胞的作用。 方法 选用浓度递增的西妥昔单抗(5～500) mg/mL和aIR3(2.5～250.0) μmol/L，单独或联合作用于HepG2细胞，观察不同时间对细胞增殖的抑制作用以及联用时的两药协同系数。 结果 单药西妥昔单抗与aIR3对HepG2细胞增殖的抑制作用均呈浓度依赖性与时间依赖性，二药单独作用于HepG2细胞72 h最大抑制率分别为42.2%、82.3%，二药联合作用于HepG2细胞72 h最大抑制率达91.8%。西妥昔单抗与аIR3不同浓度在各时间点的协同系数均小于1。 结论 西妥昔单抗和aIR3在体外对HepG2细胞的增殖均具有一定的抑制作用，联合应用时具有明显的协同效应。
[关键词] 肝癌细胞株；表皮生长因子受体；西妥昔单抗；胰岛素样生长因子—Ⅰ受体；aIR3
[中图分类号] R735.7 [文献标识码] A [文章编号] 1673—9701(2012)26—0001—03
Effects of cetuximab combined with inhibitor of IGF—ⅠR on proliferation of human hepatocellular carcinoma cell lines HepG2
HAN Chunfan1 CHEN Yingrong2 CAI Weilong1 XIE Zhonghai1 WANG Yan1 SHEN Hua1 MIN Lishan2 WEI Feng1 DAI Licheng2
1.Department of Surgery， Huzhou Central Hospital， Huzhou 313000， China； 2.Huzhou Key Molecular Medical Laboratory， Huzhou 313000， China
[Abstract] Objective To evaluate the effects of cetuximab combined with inhibitor of insulin—like growth factor—Ⅰreceptor (IGF—ⅠR) aIR3 on proliferation of human hepatocellular carcinoma cell (HCC) lines HepG2. Methods Increasing concentrations of cetuximab (5—500) mg/mL and aIR3 (2.5—250.0) μmol/L， alone or in combination were administrated to HepG2 cells. The inhibitory effects of the drugs on cell proliferation at different time points were observed；the combination index (CI) of these two agents was calculated. Results The single agent of cetuximab and aIR3 inhibited the proliferation of HCC cells in a time— and dose—dependent manner. After treatment 72—hour ......
您现在查看是摘要介绍页，详见PDF附件(2541kb)。